{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-033868","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2026-05-12T11:07:44+00:00","discovered_at":"2026-05-12T11:10:00.362945+00:00","generated_at":"2026-05-12T11:11:49.705917+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Acumen posts Q1 net loss $20.7M; Phase 2 AD topline results expected late 2026","bullets":["Cash and marketable securities totaled $128.4M as of Mar 31, 2026; funded into early 2027.","Net loss $20.7M for Q1 2026 vs $28.8M in Q1 2025; R&D expense fell to $16.5M from $25.3M.","Topline results from Phase 2 ALTITUDE-AD study (sabirnetug, early Alzheimer's) due late 2026.","Option to license two candidates from JCR EBD collaboration expected in Q2 2026.","Targeting IND filing for EBD lead candidate in mid-2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-033868","json":"https://secwatch.observer/filing/0001628280-26-033868.json","markdown":"https://secwatch.observer/filing/0001628280-26-033868.md","text":"https://secwatch.observer/filing/0001628280-26-033868.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026033868/0001628280-26-033868-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026033868/abos-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T11:11:49.705917+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}